anti-ror1 antibody-drug conjugate im-1021
Generic: Anti-ROR1 Antibody-drug Conjugate IM-1021
anti-ror1 antibody-drug conjugate im-1021: 1 clinical trial tracked.
anti-ror1 antibody-drug conjugate im-1021 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-ror1 antibody-drug conjugate im-1021, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Primary endpoint: Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)
Interventionalopen190 targetStarted 2025-02Completion 2029-0224 sites · Denmark, France, Spain, United StatesImmunome, Inc.